Radius Health Inc. (NASDAQ:RDUS)’s share price traded up 2% on Friday . The company traded as high as $57.91 and last traded at $57.55, with a volume of 1,497,564 shares. The stock had previously closed at $56.40.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, May 2nd. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a research report on Tuesday, May 31st. Cowen and Company assumed coverage on shares of Radius Health in a research report on Friday, May 6th. They set an “outperform” rating for the company. Jefferies Group reaffirmed a “hold” rating on shares of Radius Health in a research report on Friday, August 5th. Finally, HC Wainwright assumed coverage on shares of Radius Health in a research report on Monday, May 23rd. They set a “buy” rating and a $55.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $61.73.

The stock’s market cap is $2.44 billion. The firm’s 50 day moving average price is $46.90 and its 200 day moving average price is $36.99.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by $0.06. During the same quarter last year, the business earned ($0.61) EPS. Equities research analysts anticipate that Radius Health Inc. will post ($3.95) earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund raised its position in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock worth $4,249,000 after buying an additional 18,259 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Radius Health during the fourth quarter valued at approximately $1,362,000. Finally, Wells Fargo & Company MN raised its position in shares of Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock valued at $25,984,000 after buying an additional 29,601 shares during the period.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.